160 related articles for article (PubMed ID: 24162837)
41. Development of a [177Lu]BPAMD labeling kit and an automated synthesis module for routine bone targeted endoradiotherapy.
Meckel M; Nauth A; Timpe J; Zhernosekov K; Puranik AD; Baum RP; Rösch F
Cancer Biother Radiopharm; 2015 Mar; 30(2):94-9. PubMed ID: 25714451
[TBL] [Abstract][Full Text] [Related]
42.
Rizvi SFA; Naqvi SAR; Roohi S; Sherazi TA; Rasheed R
Mol Biol Rep; 2018 Dec; 45(6):1759-1767. PubMed ID: 30143975
[TBL] [Abstract][Full Text] [Related]
43. Comparative analysis of 11 different radioisotopes for palliative treatment of bone metastases by computational methods.
Guerra Liberal FD; Tavares AA; Tavares JM
Med Phys; 2014 Nov; 41(11):114101. PubMed ID: 25370676
[TBL] [Abstract][Full Text] [Related]
44. Preparation and evaluation of rhenium-188-pamidronate as a palliative treatment in bone metastasis.
Erfani M; Rahmani N; Doroudi A; Shafiei M
Nucl Med Biol; 2017 Jun; 49():1-7. PubMed ID: 28279906
[TBL] [Abstract][Full Text] [Related]
45. In vitro and in vivo characterization of 177Lu-huA33: a radioimmunoconjugate against colorectal cancer.
Almqvist Y; Steffen AC; Tolmachev V; Divgi CR; Sundin A
Nucl Med Biol; 2006 Nov; 33(8):991-8. PubMed ID: 17127172
[TBL] [Abstract][Full Text] [Related]
46. Preparation and evaluation of Lu-(177) phytate Complex for Radiosynovectomy.
Yousefnia H; Jalilian AR; Zolghadri S
World J Nucl Med; 2014 Jan; 13(1):22-7. PubMed ID: 25191108
[TBL] [Abstract][Full Text] [Related]
47. Preclinical evaluation of (177)lu-nimotuzumab: a potential tool for radioimmunotherapy of epidermal growth factor receptor-overexpressing tumors.
Vera DR; Eigner S; Beran M; Henke KE; Laznickova A; Laznicek M; Melichar F; Chinol M
Cancer Biother Radiopharm; 2011 Jun; 26(3):287-97. PubMed ID: 21711096
[TBL] [Abstract][Full Text] [Related]
48. Preparation and biological evaluation of (177)Lu conjugated PR81 for radioimmunotherapy of breast cancer.
Salouti M; Babaei MH; Rajabi H; Rasaee Mj
Nucl Med Biol; 2011 Aug; 38(6):849-55. PubMed ID: 21843781
[TBL] [Abstract][Full Text] [Related]
49. Development of [(90)Y]DOTA-conjugated bisphosphonate for treatment of painful bone metastases.
Ogawa K; Kawashima H; Shiba K; Washiyama K; Yoshimoto M; Kiyono Y; Ueda M; Mori H; Saji H
Nucl Med Biol; 2009 Feb; 36(2):129-35. PubMed ID: 19217524
[TBL] [Abstract][Full Text] [Related]
50. 177Lu labelled polyaminophosphonates as potential agents for bone pain palliation.
Chakraborty S; Das T; Unni PR; Sarma HD; Samuel G; Banerjee S; Venkatesh M; Ramamoorthy N; Pillai MR
Nucl Med Commun; 2002 Jan; 23(1):67-74. PubMed ID: 11748440
[TBL] [Abstract][Full Text] [Related]
51. Studies on the preparation and stability of samarium-153 propylene diamine tetramethylene phosphonate (PDTMP) complex as a bone seeker.
Majali MA; Mathakar AR; Shimpi HH; Banerjee S; Samuel G
Appl Radiat Isot; 2000 Dec; 53(6):987-91. PubMed ID: 11077962
[TBL] [Abstract][Full Text] [Related]
52. Demonstration of dose dependent cytotoxic activity in SW480 colon cancer cells by ¹⁷⁷Lu-labeled siRNA targeting IGF-1R.
Fathi M; Taghikhani M; Ghannadi-Maragheh M; Yavari K
Nucl Med Biol; 2013 May; 40(4):529-36. PubMed ID: 23618769
[TBL] [Abstract][Full Text] [Related]
53. 177Lu-EDTMP: a potential therapeutic bone agent.
Ando A; Ando I; Tonami N; Kinuya S; Kazuma K; Kataiwa A; Nakagawa M; Fujita N
Nucl Med Commun; 1998 Jun; 19(6):587-91. PubMed ID: 10234664
[TBL] [Abstract][Full Text] [Related]
54. (175)Yb-TTHMP as a good candidate for bone pain palliation and substitute of other radiopharmaceuticals.
Safarzadeh L
Indian J Nucl Med; 2014 Jul; 29(3):135-9. PubMed ID: 25210277
[TBL] [Abstract][Full Text] [Related]
55. Production logistics of 177Lu for radionuclide therapy.
Pillai MR; Chakraborty S; Das T; Venkatesh M; Ramamoorthy N
Appl Radiat Isot; 2003; 59(2-3):109-18. PubMed ID: 12941498
[TBL] [Abstract][Full Text] [Related]
56. Therapeutic effects of a 186Re-complex-conjugated bisphosphonate for the palliation of metastatic bone pain in an animal model.
Ogawa K; Mukai T; Asano D; Kawashima H; Kinuya S; Shiba K; Hashimoto K; Mori H; Saji H
J Nucl Med; 2007 Jan; 48(1):122-7. PubMed ID: 17204708
[TBL] [Abstract][Full Text] [Related]
57. In vitro and in vivo evaluation of direct rhenium-188-labeled anti-CD52 monoclonal antibody alemtuzumab for radioimmunotherapy of B-cell chronic lymphocytic leukemia.
De Decker M; Bacher K; Thierens H; Slegers G; Dierckx RA; De Vos F
Nucl Med Biol; 2008 Jul; 35(5):599-604. PubMed ID: 18589304
[TBL] [Abstract][Full Text] [Related]
58. Optimization of radioimmunotherapy of renal cell carcinoma: labeling of monoclonal antibody cG250 with 131I, 90Y, 177Lu, or 186Re.
Brouwers AH; van Eerd JE; Frielink C; Oosterwijk E; Oyen WJ; Corstens FH; Boerman OC
J Nucl Med; 2004 Feb; 45(2):327-37. PubMed ID: 14960657
[TBL] [Abstract][Full Text] [Related]
59. Preparation and biological evaluation of 153Sm-DOTMP as a potential agent for bone pain palliation.
Chakraborty S; Das T; Banerjee S; Chaudhari PR; Sarma HD; Venkatesh M; Pillai MR
Nucl Med Commun; 2004 Dec; 25(12):1169-76. PubMed ID: 15640774
[TBL] [Abstract][Full Text] [Related]
60. Preparation of 177Lu-labeled oxine in lipiodol as a possible agent for therapy of hepatocellular carcinoma: a preliminary animal study.
Subramanian S; Das T; Chakraborty S; Sarma HD; Banerjee S; Samuel G; Venkatesh M
Cancer Biother Radiopharm; 2010 Oct; 25(5):539-43. PubMed ID: 20849309
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
